|
||||||||||||||||||||
Title: |
Clinical Efficacy of Osimertinib in Targeted Therapies of Patients with Non–Small Cell Lung Cancer A Randomized Controlled Trial | |||||||||||||||||||
| Authors: | De-bin Zhuo, B.S., Gui-lin Zheng, B.S., Qing-yu Lin, B.S., Juan Lin, M.M., and Shan-zuan Wang, M.D. | |||||||||||||||||||
|
Objective: To explore the clinical efficacy of osimertinib in targeted therapies of patients with non–small cell lung cancer (NSCLC), thus providing experimental data for clinical treatment of this disease.
Study Design: A total of 120 patients with NSCLC who underwent treatment in our hospital between November 2020 and August 2021 were enrolled. These patients were divided randomly into platinum-pemetrexed chemotherapy group (PP) (n=6) and osimertinib targeted therapy group (OT) (n=6). A CT scan was employed for examining patients before and after treatment, and the occurrence of adverse reactions was recorded. The levels of tumor-related markers in serum including carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), neuron-specific enolase (NSE), and carbohydrate antigen 125 (CA125) were compared before and after treatment. Flow cytometry was used to detect the proportion of CD3+, CD4+, and CD8+ T lymphocyte subsets in peripheral blood of patients. Kaplan-Meier method was used to calculate the survival of patients after treatment. Results: There was no significant difference in the general data between the 2 groups. According to CT imaging, as compared with the PP group, tumor volume was decreased significantly in the OT group. After treatment, the tumor-related markers in the serum and adverse reactions in the OT group were significantly less than those of the PP group; also, the proportions of CD3+, CD4+, and CD8+ T lymphocytes were higher than those of the PP group. Compared with the PP group, the survival of patients after treatment was higher in the OT group. Conclusion: Osimertinib (a targeted therapy) shows better efficacy than platinum-pemetrexed (a chemotherapy) in the treatment of NSCLC and has a good therapeutic prospect. |
||||||||||||||||||||
| Keywords: | carcinoma, non-small-cell lung; lung cancer; lung neoplasms; non-small cell lung cancer; osimertinib; pemetrexed | |||||||||||||||||||
| Acrobat Reader 7.0 is recommended to properly view and print the article.
Reader can be downloaded from  |
||||||||||||||||||||
